Advertisement
U.S. markets close in 1 hour 53 minutes
  • S&P 500

    5,082.11
    -6.69 (-0.13%)
     
  • Dow 30

    39,127.53
    -4.00 (-0.01%)
     
  • Nasdaq

    16,020.13
    +23.31 (+0.15%)
     
  • Russell 2000

    2,021.61
    +4.92 (+0.24%)
     
  • Crude Oil

    77.73
    +1.24 (+1.62%)
     
  • Gold

    2,038.90
    -10.50 (-0.51%)
     
  • Silver

    22.50
    -0.49 (-2.12%)
     
  • EUR/USD

    1.0850
    +0.0027 (+0.25%)
     
  • 10-Yr Bond

    4.2970
    +0.0370 (+0.87%)
     
  • GBP/USD

    1.2679
    +0.0006 (+0.05%)
     
  • USD/JPY

    150.7420
    +0.3020 (+0.20%)
     
  • Bitcoin USD

    53,526.39
    +1,977.70 (+3.84%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,684.30
    -21.98 (-0.29%)
     
  • Nikkei 225

    39,233.71
    +135.03 (+0.35%)
     

Recap: Antares Pharma Q4 Earnings

 

Shares of Antares Pharma (NASDAQ:ATRS) were unchanged after the company reported Q4 results.

Quarterly Results

Earnings per share were flat 0.00% over the past year to $0.03, which were in line with the estimate of $0.03.

Revenue of $44,133,000 up by 16.63% from the same period last year, which beat the estimate of $40,750,000.

Outlook

The upcoming fiscal year's revenue expected to be between $175,000,000 and $200,000,000.

Conference Call Details

Date: Mar 02, 2021

View more earnings on ATRS

Time: 08:30 AM

ET Webcast URL: https://streaming.webcasts.com/starthere.jsp?ei=1424766&tp_key=38c62cb12a

Technicals

Company's 52-week high was at $5.07

52-week low: $1.60

Price action over last quarter: Up 57.89%

Company Description

Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The company's products include OTREXUP, Elestrin, Gelnique, Makena, and others.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement